An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
← catalyst calendarSponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →. With ViaCyte.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
5actual
Sites
2
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Patients to be followed up in the VCTX-201 study
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-20 | actual | When the study began enrolling |
| Primary completion | 2025-08-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-08 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Autoimmune Diseases
- Immune System Diseases
Intervention
- Combination product: VCTX211
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events with causality related to VCTX211 units, the surgical procedures and/or medical interventions required to implant and explant the VCTX211 units.
measured From implantation up to 12 months post implantation
Assess the clinical efficacy of VCTX211 units via evaluation of C-peptide increase from the baseline.
measured From implantation up to 12 months post implantation
Publications
- PMID 42023429 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed